trending Market Intelligence /marketintelligence/en/news-insights/trending/m65sxoxame03mdbbqr5rnq2 content esgSubNav
In This List

Agios CEO to step down; will be replaced by former Celgene president/COO

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Agios CEO to step down; will be replaced by former Celgene president/COO

Agios Pharmaceuticals Inc. said David Schenkein will step down as CEO on Feb. 1, 2019 and become executive chairman of the board.

Schenkein has served as CEO of the Cambridge, Mass.-based company since 2009 and oversaw the U.S. approval of two cancer medicines.

Jacqualyn Fouse, who joined Agios' board in December 2017, will succeed Schenkein as CEO. She will remain on the board of directors.

Fouse previously worked as president and COO of Summit, N.J.-based biopharmaceutical company Celgene Corp.

Further, Agios Chairman John Maraganore will become a director when Schenkein becomes chairman.